Toshihiko Fukuoka

  • Citations Per Year
Learn More
The incidence and mortality of lung cancer have increased worldwide over the last decades, with an observed increased incidence particularly among elderly populations. It has not yet been determined whether erlotinib therapy exhibits the same efficacy and safety in elderly and younger patients with non-small-cell lung cancer (NSCLC). The aim of this(More)
To evaluate the efficacy and safety of erlotinib for non-small cell lung cancer (NSCLC), we performed a population-based observational study. The study involved 307 patients treated with erlotinib at 14 sites (17 departments) in Ibaraki (Japan) between December 2007 and December 2010. The tumor response and disease control rates were 11.1 and 46.3% in all(More)
An 87-year-old man was admitted complaining of cough after he had been treated with drugs at another hospital. Chest X-ray revealed multiple nodules, and chest computed tomography (CT) showed metastatic lung tumors. Abdominal CT revealed staining of the outer portion of the prostate by contrast medium, though this finding was considered nonspecific and(More)
  • 1